Your browser doesn't support javascript.
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
Skelly, Donal T; Harding, Adam C; Gilbert-Jaramillo, Javier; Knight, Michael L; Longet, Stephanie; Brown, Anthony; Adele, Sandra; Adland, Emily; Brown, Helen; Tipton, Tom; Stafford, Lizzie; Mentzer, Alexander J; Johnson, Síle A; Amini, Ali; Tan, Tiong Kit; Schimanski, Lisa; Huang, Kuan-Ying A; Rijal, Pramila; Frater, John; Goulder, Philip; Conlon, Christopher P; Jeffery, Katie; Dold, Christina; Pollard, Andrew J; Sigal, Alex; de Oliveira, Tulio; Townsend, Alain R; Klenerman, Paul; Dunachie, Susanna J; Barnes, Eleanor; Carroll, Miles W; James, William S.
  • Skelly DT; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Harding AC; Nuffield Department of Clinial Neurosciences, University of Oxford, Oxford, UK.
  • Gilbert-Jaramillo J; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Knight ML; James and Lillian Martin Centre, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
  • Longet S; James and Lillian Martin Centre, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
  • Brown A; James and Lillian Martin Centre, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
  • Adele S; Public Health England, Porton Down, UK.
  • Adland E; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Brown H; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Tipton T; Peter Medawar Building for Pathogen Research, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Stafford L; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Johnson SA; Public Health England, Porton Down, UK.
  • Amini A; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Tan TK; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Schimanski L; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Huang KA; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Rijal P; Medical Sciences Division, University of Oxford, Oxford, UK.
  • Frater J; Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Conlon CP; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Jeffery K; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Dold C; Centre for Translational Immunology, Chinese Academy of Medical Sciences, Oxford Institute, University of Oxford, Oxford, UK.
  • Pollard AJ; Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, and Taipei Medical University, Taipei, Taiwan.
  • Sigal A; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • de Oliveira T; Centre for Translational Immunology, Chinese Academy of Medical Sciences, Oxford Institute, University of Oxford, Oxford, UK.
  • Dunachie SJ; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Barnes E; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Carroll MW; Peter Medawar Building for Pathogen Research, Department of Paediatrics, University of Oxford, Oxford, UK.
  • James WS; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nat Commun ; 12(1): 5061, 2021 08 17.
Article in English | MEDLINE | ID: covidwho-1361634
ABSTRACT
The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-25167-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-25167-5